Gossamer Bio 2025 Q2 Earnings Sharp Net Loss Amid Revenue Drop

Gossamer Bio reported its second-quarter 2025 earnings on August 6, 2025. The results showed a significant shift from a year-ago profit to a loss, driven by a sharp decline in revenue and the absence of one-time gains. The company offered no earnings guidance, with its focus now firmly on late-stage clinical developments and commercial preparations for seralutinib.

Revenue

Gossamer Bio’s total revenue in Q2 2025 plummeted by 88.0% year-over-year to $11.49 million, compared to $95.84 million in the same period of 2024. The decline was largely due to the absence of a one-time $88.8 million license sale from 2024. For the current quarter, the company’s revenue came entirely from its collaboration with Chiesi Group, which includes $7.6 million in cost reimbursement. This marked a significant drop from the previous year’s collaboration revenue of $7.09 million.

Earnings/Net Income

The company swung to a net loss of $38.27 million in Q2 2025, or $0.17 per share, compared to a net income of $49.23 million, or $0.22 per share, in the same period of 2024. The year-over-year change was primarily due to the absence of the one-time license revenue from the prior year. This represents a 177.7% deterioration in net income, marking a significant shift from profit to loss.

Price Action

The stock price of Gossamer Bio edged down 0.69% during the latest trading day but showed a 10.20% gain for the most recent full week. The stock surged 74.19% month-to-date, reflecting strong investor interest amid its advancing clinical programs.

Post Earnings Price Action Review

The strategy of purchasing GOSS shares following the Q2 earnings report and holding for 30 days resulted in a -92.97% return, significantly underperforming the 48.58% benchmark return. This led to an excess return of -141.55% and a compound annual growth rate of -60.01% over three years. The strategy also recorded a maximum drawdown of 0.00%, indicating a complete loss in value.

CEO Commentary

Faheem Hasnain, Chairman, Co-Founder, and CEO, emphasized the company’s transition toward a commercial organization, driven by progress in preparing for the commercialization of seralutinib in partnership with Chiesi Group. He highlighted the significance of the upcoming February 2026 topline results from the Phase 3 PROSERA Study in pulmonary arterial hypertension (PAH), which could serve as the foundation for a multi-billion-dollar franchise. Hasnain reiterated the company’s commitment to operational excellence and unmet patient needs, with key strategic priorities including the activation of the Phase 3 SERANATA Study in PH-ILD in Q4 2025.

Guidance

The company expects its cash, cash equivalents, and marketable securities of $212.9 million as of June 30, 2025, to fund operations into 2027. It remains focused on key clinical milestones, including the topline data from the Phase 3 PROSERA Study in February 2026 and the activation of the Phase 3 SERANATA Study in Q4 2025.

Additional News

Gossamer Bio announced the completion of enrollment in the Phase 3 PROSERA Study for seralutinib in pulmonary arterial hypertension (PAH), involving 390 patients. The study, a global, double-blind, placebo-controlled trial, is evaluating the drug as an add-on therapy for PAH patients. The primary endpoint is the change in six-minute walk distance (6MWD) from baseline compared to placebo at week 24. A poster on seralutinib was also presented at the American Thoracic Society (ATS) 2025 International Conference, highlighting mechanisms of reverse remodeling in PAH. Additionally, the company plans to initiate the Phase 3 SERANATA Study in PH-ILD in Q4 2025, with a projected enrollment of 480 patients randomized to receive one of two dosing regimens or placebo.